search
Back to results

Effect of Vitamin D3 on Cardiovascular Risk Factors

Primary Purpose

Hypertensive Disease, Deficiency of Vitamin D3

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Vitamin D3
Placebo
Sponsored by
Martin-Luther-Universität Halle-Wittenberg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertensive Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • human volunteers with mild hypertension

Exclusion Criteria:

  • use of antihypertensive medication
  • use of vitamin d or calcium supplements
  • known renal, inflammatory or malignant diseases
  • hypercalcemia or hypercalciuria
  • participation in other clinical studies
  • use of tanning booths during the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    vitamin d

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    blood pressure
    major outcome variable is the decrease oy systolic blood pressure in the treatment group in comparison with the placebo group.

    Secondary Outcome Measures

    Full Information

    First Posted
    November 4, 2011
    Last Updated
    October 10, 2018
    Sponsor
    Martin-Luther-Universität Halle-Wittenberg
    Collaborators
    German Federal Ministry of Education and Research
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01501916
    Brief Title
    Effect of Vitamin D3 on Cardiovascular Risk Factors
    Official Title
    Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2012 (undefined)
    Primary Completion Date
    April 2013 (Actual)
    Study Completion Date
    December 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Martin-Luther-Universität Halle-Wittenberg
    Collaborators
    German Federal Ministry of Education and Research

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The aim of this study is to investigate whether a supplementation of Vitamin D3 can be used to reduce atherosclerotic risk factors.
    Detailed Description
    It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 can lower blood pressure in mildly hypertensive subjects who are naive to antihypertensive medication, whether Vitamin D reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids. major outcomes: - decrease of systolic blood pressure in the treatment group in comparison with the placebo group

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertensive Disease, Deficiency of Vitamin D3

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    250 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    vitamin d
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Vitamin D3
    Other Intervention Name(s)
    cholecalciferol
    Intervention Description
    daily dosage of 50 µg Vitamin D3 for 8 weeks
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Placebo
    Intervention Description
    daily intake of placebo
    Primary Outcome Measure Information:
    Title
    blood pressure
    Description
    major outcome variable is the decrease oy systolic blood pressure in the treatment group in comparison with the placebo group.
    Time Frame
    after 8 weeks of supplementation

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: human volunteers with mild hypertension Exclusion Criteria: use of antihypertensive medication use of vitamin d or calcium supplements known renal, inflammatory or malignant diseases hypercalcemia or hypercalciuria participation in other clinical studies use of tanning booths during the study
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jutta Dierkes, Prof. Dr.
    Organizational Affiliation
    Institut für Agrar- und Ernährungswissenschaften
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Effect of Vitamin D3 on Cardiovascular Risk Factors

    We'll reach out to this number within 24 hrs